IVERIC bio to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, MD, Executive Vice President and Chief Strategy and Business Officer, will present an overview of the Company at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 9:10 a.m. Eastern Time.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, August 4, 2020
Information
Tags: 
Biotechnology, Health, Pharmaceutical, Optical, Clinical trials, Given names, Financial markets, Agencies of the European Union, European Union, European Securities and Markets Authority, Finance, Esma, Wedbush Securities
Geotags: 
United States, NEW YORK
⚠generated by AI ↴
Summary
Key Points: 
  • IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, MD, Executive Vice President and Chief Strategy and Business Officer, will present an overview of the Company at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 9:10 a.m. Eastern Time.
  • An archived replay of the webcast will be available on the Companys website immediately following the conference and for at least two weeks thereafter.
  • IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs.
  • While IVERIC bio may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so.


IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, MD, Executive Vice President and Chief Strategy and Business Officer, will present an overview of the Company at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 9:10 a.m. Eastern Time.

Investors and the general public are invited to listen to a live webcast of the presentation available on the Investor / Events & Presentations section of the IVERIC bio website at www.ivericbio.com. An archived replay of the webcast will be available on the Company’s website immediately following the conference and for at least two weeks thereafter.

About IVERIC bio

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company, please visit www.ivericbio.com.

Forward-looking Statements

Any statements in this press release about IVERIC bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent IVERIC bio’s views only as of the date of this press release. IVERIC bio anticipates that subsequent events and developments will cause its views to change. While IVERIC bio may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so.

ISEE-G

Copyright: 
Copyright Business Wire 2020